JP Morgan Maintains Overweight on AtriCure, Raises Price Target to $48

Benzinga · 12/16/2025 15:36
JP Morgan analyst Lilia-Celine Lozada maintains AtriCure (NASDAQ:ATRC) with a Overweight and raises the price target from $42 to $48.